全球知名法律评级机构钱伯斯于近期出版了《钱伯斯生命科学全球实务指南》（2024年）（“《指南》”）。汉坤继续受邀撰写了《指南》“中国篇：趋势与发展”部分，参与撰写的作者包括朱敏、龚雅玲、顾泱、柴璐、李英和袁世也。
该《指南》覆盖了21个司法辖区，探讨了生命科学领域面临的最新挑战，包括监管机构的决策、临床试验、药品和医疗器械的生产和营销、产品定价、数字医疗、专利以及与后新冠疫情时代的最新进展。《指南》“中国篇：趋势与发展”涵盖了生命科学领域VC/PE投资、并购和许可交易的重要变化、药品和医疗器械方面的监管趋势、有关商业贿赂、数据合规、ESG（环境、社会和企业治理）方面的合规实践、生命科学领域的知识产权新规和税收优惠政策等方面的内容。
汉坤拥有专门从事生命科学和医疗健康业务的律师团队，在该领域具有良好的口碑和声望，已连续数年被钱伯斯、The Legal 500、Asialaw Profiles、《商法》等知名法律媒体评为该领域的领先中国律所。汉坤致力于向生命科学与医疗健康行业客户提供包括私募股权和风险投资、兼并和收购、境内外资本市场、授权许可和药品资产交易、知识产权、合规和监管、数据保护及争议解决等在内的全方位法律服务。
Han Kun authors the China chapter of Chambers Life Sciences Global Practice Guide (2024)
The world's leading legal directory Chambers and Partners recently published its Life Sciences Global Practice Guide (2024) (the "Guide"). Han Kun again contributed the China chapter of the Guide’s Trends and Developments section. The contributors include Min Zhu, Yaling (Michelle) Gon, Yang (Aaron) Gu, Lu Chai, Dr. Ying Li, and Shiye Yuan.
The Guide features 21 jurisdictions and provides the latest information on challenging the decisions of regulatory bodies; clinical trials; the marketing, manufacturing, and distribution of pharmaceuticals and medical devices; pricing; digital healthcare; patents; and post COVID-19 developments. The Guide's China chapter covers major changes in venture capital/private equity financing, merger and acquisition, and license-in/out deals in the life sciences industry; drug and medical device regulatory developments; compliance practices in respect of commercial bribery, data compliance, and ESG (environmental, social and governance); and new Chinese intellectual property regulations and tax incentives for the life sciences industry.
Han Kun has a dedicated life sciences and healthcare team and has been consistently ranked as a leading law firm in the life sciences and healthcare sector by authoritative legal directories, including Chambers and Partners, The Legal 500, Asialaw Profiles, and China Business Law Journal. The firm is committed to providing clients in the life sciences and healthcare sector with comprehensive legal services, including private equity and venture capital, mergers and acquisitions, onshore and offshore capital markets, pharmaceutical license in/out, and asset sale/purchase transactions, intellectual property, compliance and regulatory, data protection, and dispute resolution.
如需阅读“《钱伯斯生命科学全球实务指南》（2024年）”，请点击：
